Table 1. Clinical and Pathologic Characteristics of 89 Study Patients.
| Characteristics | Data | |
|---|---|---|
| Age, years | 62.1 ± 8.3 | |
| Sex, male:female | 64:25 | |
| Recurrence | ||
| Yes | 58 (65.2) | |
| No | 31 (34.8) | |
| Tumor size, cm | 5.8 ± 3.2 | |
| Histologic grade | ||
| Well differentiated | 17 (19.1) | |
| Moderately differentiated | 49 (55.1) | |
| Poorly differentiated | 23 (25.8) | |
| Multiplicity | 15 (16.9) | |
| Extrahepatic extension | 28 (31.5) | |
| Vascular invasion | 42 (47.2) | |
| Regional lymph node metastasis | 23 (25.8) | |
| Underlying hepatitis | 32 (36.0) | |
| Laboratory finding | ||
| CA 19-9, U/mL | 3252.3 ± 11292.2 | |
| CEA, ng/mL | 7.2 ± 16.5 | |
| AST, IU/L | 36.7 ± 37.3 | |
| ALT, IU/L | 40.4 ± 64.0 | |
| Total bilirubin, mg/dL | 1.0 ± 1.1 | |
| Albumin, g/dL | 4.1 ± 0.4 | |
Data are mean ± standard deviation or number of patients with percentage in parentheses. ALT = alanine aminotransferase, AST = aspartate transaminase, CA 19-9 = carbohydrate antigen 19-9, CEA = cancer embryonic antigen